|Articles|June 1, 2011

Applied Clinical Trials-06-01-2011
Volume 20
Issue 6

Applied Clinical Trials Digital Edition - June 2011

CRO/SPONSORS : Integrated Drug Safety Archiving in the United Kingdom Language and Culture in Global Trials INFORMATION TECHNOLOGY : Cloud Computing - Pharmacovigilance TRIAL DESIGN : Placebo Effect of Transdermal NSAIDs SITES : IRB Registration SUBJECT RECRUITMENT : Formula for Recruitment Success Also in this issue : e-Submissions Gain Support, Personalized Medicine, iPad Apps for Clinical Trials, R&D Productivity

External Link - article-821541.pdf

Articles in this issue

over 15 years ago

Article

Patient Recruitment Feasibility

over 15 years ago

Article

Archiving Approach in the UK

over 15 years ago

Article

Taking Clinical Computing in Hand

over 15 years ago

Article

Business and News Update June 2011

over 15 years ago

Article

Getting Personal Over Personalized Medicine

over 15 years ago

Article

Early Use of Antiretrovirals May Reduce HIV Transmission

over 15 years ago

Article

Moffitt Cancer Center Chooses Oracle

over 15 years ago

Article

Current Challenges of Poor R&D

over 15 years ago

Article

Placebo Effect of Transdermal NSAIDS

over 15 years ago

Article

Language & Culture in Global Clinical Trials

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© putilov_denis - © putilov_denis - stock.adobe.com

October 28th, 2026

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.

October 28th, 2026

What It Would Take to Make Community Trials Accessible and Scalable

In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.

October 28th, 2026

ACT Brief: Legacy Trial Workflows, Medical Writing Talent Gaps, and Post-Exposure COVID Prevention

In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure

October 27th, 2026

Closing the Medical Writing Capacity Gap: Why Training Beats Technology

Medical writing capacity pressure is fundamentally a talent development problem, not a technology problem, since hybrid resourcing and AI cannot substitute for the experienced judgment needed to review AI output and mentor the next generation of writers.

October 27th, 2026

Why Legacy Trial Workflows Weigh So Heavily on Community and Rural Clinics

In this video interview, Kent Thoelke, CEO of Paradigm Health, describes how manual eligibility screening and swivel-chair data entry force community sites to trade billable patient care for research, and why that burden is so hard to absorb.

October 27th, 2026

ACT Brief: Community Trial Cost Barriers, Measuring What Matters, and Prostate Cancer Approval

In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.

October 26th, 2026

How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patient cost barriers and site infrastructure challenges must be solved together to close the participation gap in community and rural clinical trials.

© FlowStudio - © FlowStudio - stock.adobe.com

October 26th, 2026

Measuring What Matters: Realigning Clinical Endpoints with Patient Reality

Patients don’t experience primary endpoints, so trials that stop at biomarkers and rigid rating scales risk declaring success while leaving daily burden untouched, and digital tools only deliver meaningful evidence when they are co-designed with patients and deployed with restraint.